静脉用盐酸托烷司琼及联合沙利度胺治疗卵巢癌化疗所致恶心呕吐疗效及安全性研究

Efficacy and safety of intravenous tropisetron hydrochloride combined with thalidomide in the treatment of nausea and vomiting induced by chemotherapy in ovarian cancer

目的探讨静脉用盐酸托烷司琼及联合沙利度胺治疗卵巢癌化疗所致恶心呕吐的疗效及安全性。方法回顾性分析2015年1月至2017年7月中国医科大学附属盛京医院收治的94例卵巢癌患者,根据治疗方法将其分为两组,各47例。两组均采用紫杉醇联合卡铂(TC)方案化疗,对照组使用盐酸托烷司琼静脉滴注治疗,研究组在对照组的基础上加用沙利度胺口服治疗。分别评价两组急性期和延迟期止恶心、止呕吐的疗效,统计两组欧洲肿瘤研究与治疗中心生存质量核心问卷评分,比较两组不良反应情况。结果研究组急性期和延迟期止恶心、止呕吐总有效率高于对照组(P <0. 05);两组化疗后15 d欧洲肿瘤研究与治疗中心生存质量核心问卷评分均升高(P <0. 05),且研究组高于对照组(P <0. 05);两组不良反应发生率比较差异无统计学意义(P> 0. 05)。结论与静脉用盐酸托烷司琼相比,盐酸托烷司琼联合口服沙利度胺治疗卵巢癌化疗所致恶心呕吐疗效更好,且安全性高。

Objective To compare and analyze the efficacy and safety of tropisetron hydrochloride injection and thalidomide in the treatment of nausea and vomit induced by chemotherapy of ovarian cancer. Methods A retrospective analysis of 94 patients with ovarian cancer admitted to Shengjing Hospital Affiliated to China Medical University from January 2015 to July 2017 was divided into two groups according to the treatment methods,with 47 cases in each group. Both groups were treated with paclitaxel plus carboplatin（ TC）regimen,and the control group was treated with intravenous infusion of tropisetron hydrochloride. The efficacies on stopping nausea and vomit in acute and delayed periods of two groups were evaluated respectively,the Europe Organization for Research And Treatment of Cancer Quality of Life Questionnaire-Core 30（ EORTC QLQ-C 30） scores of the two groups were statistically analyzed,and the adverse reactions in the two groups were compared. Results The total effective rates of stopping nausea in acute and delayed periods of the study group were significantly higher than those of the control group（ P〈0. 05）; the total effective rates of stopping vomit in the acute and delayed periods of the study group were significantly higher than those of the control group（ P〈0. 05）; the EORTC QLQ-C30 scores at 15 d after chemotherapy in the two groups were significantly increased（ P〈0. 05）,and the study group was significantly higher than the control group（ P〉0. 05）; there was no significant difference in the incidence of adverse reactions between the study group and the control group（ P〈0. 05）. Conclusion Compared with intravenous tropisetron hydrochloride,tropisetron hydrochloride combined with oral thalidomide is more effective and safer in the treatment of nausea and vomiting caused by chemotherapy in ovarian cancer.